Press release
Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2017
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2017, provides an overview of the Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline landscape.
Proliferative diabetic retinopathy (PDR) is the most severe type of diabetic retinopathy. Proliferative diabetic retinopathy occurs where fragile new blood vessels form on the surface of the retina over time. These abnormal vessels can bleed or develop scar tissue causing severe loss of sight. Predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use. Symptoms include spots or dark strings floating in vision, vision loss, fluctuating vision, blurred vision and difficulty with color perception.
To Enquire about this Report please visit @ https://www.reportsworldwide.com/report/proliferative-diabetic-retinopathy-pdr-pipeline-review-h1-2017
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Proliferative Diabetic Retinopathy (PDR) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 3, 1 and 6 respectively.
Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
About ReportsWorldwide.com
ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.
Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
Phone +1 (617) 398-4994
Fax +1 (617) 398-4995
abigail@reportsworldwide.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2017 here
News-ID: 566609 • Views: …
More Releases from ReportsWorldwide
World Deep Brain Stimulation Market Top Segments, Key Players Revenue, Growth Ra …
The World Deep Brain Stimulation Market is estimated to represent a global market of USD 751.8 million by 2017 with growth rate of 18.2%. Deep brain stimulation (DBS) procedure is primarily used for the treatment of neuropsychiatric disorders such as mood disorder, dementia, anxiety and others. The procedure involve the use of neurotransmitter (brain pacemaker) that enables to transmit electric impulses to the specific target of brain cells. Increasing incidence…
New report explores the Gene Editing Market : Ushering The Next Breakthrough in …
Boston, MA
ReportsWorldwide has announced the addition of a new report title Gene Editing The Next Breakthrough in Regenerative Medicine to its growing collection of premium market research reports.
Genome editing is a type of genetic engineering in which DNA is replaced, inserted or deleted in a living organism's ggenome using engineered molecular scissors.
Believed to be one of the great biotechnology breakthroughs, gene editing is a powerful tool in pharmaceutical research that…
Global In-Building Wireless BTSController-based Small Cells Market Analysis and …
Boston, MA
ReportsWorldwide has announced the addition of a new report title Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021 to its growing collection of premium market research reports.
This report covers the leading in-building wireless enterprise BTS/controller-based small cells network equipment manufacturers:
• CommScope/Airvana
• Comba Telecom
• Ericsson
• Huawei Technologies
• Nokia
• SpiderCloud
• ZTE Corporation
This report covers the global market share for 2016 shipments as well as a forecast for 2017-2021.
To view a detailed description and Table of…
More Releases for Proliferative
Major Growth Driver Identified in 2025 Non-Proliferative Diabetic Retinopathy Ma …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Non-Proliferative Diabetic Retinopathy Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market for non-proliferative diabetic retinopathy has seen significant growth recently, expanding from $2.62 billion in 2024 to $2.84 billion in 2025, with an 8.4% compound annual growth rate (CAGR). The increased growth during…
Evolving Market Drivers In The Non-Proliferative Diabetic Retinopathy Industry: …
The Non-Proliferative Diabetic Retinopathy Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Non-Proliferative Diabetic Retinopathy Market Size During the Forecast Period?
The non-proliferative diabetic retinopathy market is growing steadily, from $2.62 billion in 2024 to $2.84 billion in 2025 at a CAGR…
Key Influencer in the Non-Proliferative Diabetic Retinopathy Market 2025: Surgin …
What Is the Forecasted Market Size and Growth Rate for the Non-Proliferative Diabetic Retinopathy Market?
The market size for non-proliferative diabetic retinopathy has seen substantial growth in recent years. The projected growth is from $2.62 billion in 2024 to $2.84 billion in 2025, with a compound annual growth rate (CAGR) of 8.4%. The growth observed in the historic period is due to factors such as a rise in diabetes cases, an…
Global Proliferative Diabetic Retinopathy Research and Market Analysis 2018
ResearchMoz include new market research report "Proliferative Diabetic Retinopathy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2026" to its huge collection of research reports.
Proliferative diabetic retinopathy prevails as leading cause of blindness across industrialized countries worldwide. Although remarkable advancements have been made in the diagnosis and treatment of the disease, several imperative management questions as well as treatment deficiencies continue to persist unanswered. The…
Proliferative Vitreoretinopathy Market: Global Trends, Analysis and Forecast 202 …
Proliferative vitreoretinopathy (PVR) remains the most commonly observed failure in the surgery of rhegmatogenous retinal detachment (RRD), albeit substantial efforts have been taken to better understand and manage the condition in the past. Basic research indicates that proliferative vitreoretinopathy illustrates scarring - end-stage of wound healing process, which occurs post-retinal detachment surgery. Current medical treatment for PVR has been directed toward the prevention of inflammation – first stage of wound-healing…
Proliferative Vitreoretinopathy Market to Remain Lucrative During 2027
The most frequent and traumatic complication faced post-rhegmatogenous retinal detachment (RRD), proliferative vitreoretinopathy (PVR) continues to be a bottleneck in developing new surgical techniques for diseases related to retina such as retinal pigment epithelium transplantation, and macular translocation. Posterior contraction of the membranes formed on either sides of retina that are a result of PVR, and shortening of retina are key complications that prevent reattachment of retina.
Report overview @ https://www.xploremr.com/report/1499/proliferative-vitreoretinopathy-market
Complex…
